TAAR1 and cytomegalovirus infection: Recently, we have studied the immunomodulatory effect of Tα1 in a SARS-CoV-2 scenario [10] and during HCMV infection, demonstrating that Tα1 treatment might support its use as an adjuvant for therapeutic treatment with cell therapies or with routine HCMV drugs in immunocompromised patients [11].